Atlas Trials

A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era

Clinical trial NCT04624971 · UNKNOWN

Trial details

NCT number
NCT04624971
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Study type
OBSERVATIONAL
Diffuse Large B Cell Lymphoma
Start date
2020-11-01
Primary completion
2020-11-01
Enrollment
2000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.